Detection of colistin heteroresistance in Acinetobacter baumannii from blood and respiratory isolates.

[1]  Neang S. Ly,et al.  Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies. , 2016, The Journal of antimicrobial chemotherapy.

[2]  K. Porter,et al.  Colistin combination therapy improves microbiologic cure in critically ill patients with multi-drug resistant gram-negative pneumonia , 2016, European Journal of Clinical Microbiology & Infectious Diseases.

[3]  M. Valvano,et al.  Antimicrobial Heteroresistance: an Emerging Field in Need of Clarity , 2015, Clinical Microbiology Reviews.

[4]  J. Bosso,et al.  Adverse Reactions Associated with Systemic Polymyxin Therapy , 2015, Pharmacotherapy.

[5]  J. Li,et al.  Colistin and polymyxin B: peas in a pod, or chalk and cheese? , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  A Forrest,et al.  Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients , 2011, Antimicrobial Agents and Chemotherapy.

[7]  D. Sofianou,et al.  Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. , 2011, The Journal of antimicrobial chemotherapy.

[8]  Clsi.  Performance Standards for Antimicrobial Susceptibility Testing: Twenty-First Informational Supplement , 2010 .

[9]  You-ning Liu,et al.  In Vitro Antimicrobial Activity and Mutant Prevention Concentration of Colistin against Acinetobacter baumannii , 2010, Antimicrobial Agents and Chemotherapy.

[10]  R. C. Hernan,et al.  Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. , 2009 .

[11]  A. Armaganidis,et al.  Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria , 2009, Antimicrobial Agents and Chemotherapy.

[12]  J. Turnidge,et al.  Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. , 2009, The Journal of infection.

[13]  Jian Li,et al.  Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. , 2007, The Journal of antimicrobial chemotherapy.

[14]  C. Murray,et al.  Colistin Heteroresistance in Acinetobacter and Its Association with Previous Colistin Therapy , 2007, Antimicrobial Agents and Chemotherapy.

[15]  J. Kluytmans,et al.  Comparative Evaluation of the VITEK 2, Disk Diffusion, Etest, Broth Microdilution, and Agar Dilution Susceptibility Testing Methods for Colistin in Clinical Isolates, Including Heteroresistant Enterobacter cloacae and Acinetobacter baumannii Strains , 2007, Antimicrobial Agents and Chemotherapy.

[16]  J. Li,et al.  In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. , 2007, The Journal of antimicrobial chemotherapy.

[17]  J. Li,et al.  Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii , 2006, Antimicrobial Agents and Chemotherapy.

[18]  J. Bartlett,et al.  Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  H. Chambers,et al.  Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods , 2003, Antimicrobial Agents and Chemotherapy.